INVESTORS

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology and Nomination of ACH-4471, a Novel Small Molecule Factor D Inhibitor, for Clinical Development
- Presentation will highlight ACH-4471, a highly potent, specific, and orally-administered factor D inhibitor, and preclinical data on its ability to block hemolysis of paroxysmal nocturnal hemoglobinuria (PNH) cells; mitigate the accumulation of C3 fragments; and its inhibitory effect against
View HTML
Toggle Summary Achillion Appoints Dr. Frank Verwiel to Board of Directors
NEW HAVEN, Conn., Dec. 16, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the appointment of Frank Verwiel, M.D., former President and Chief Executive Officer of Aptalis Pharma, to Achillion's Board of Directors.
View HTML
Toggle Summary Achillion Appoints Dr. Joel Barrish as Chief Scientific Officer
NEW HAVEN, Conn., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that Joel Barrish, Ph.D., has been named the Company's Chief Scientific Officer (CSO) and Executive Vice President, effective January 4, 2016.
View HTML
Toggle Summary Achillion Announces Appointments of Martha Manning as General Counsel and Amy Jennings as Head of Regulatory Affairs
NEW HAVEN, Conn., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the addition of two members to the senior management team. Martha Manning, Esq., joins Achillion as Executive Vice President, General Counsel and Secretary effective February 1, 2016.
View HTML
Toggle Summary Achillion to Present at the Leerink Partners 5th Annual Global Healthcare Conference
NEW HAVEN, Conn., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the Leerink Partners 5 th Annual Global Healthcare Conference on
View HTML
Toggle Summary Achillion Initiates Phase 1 Study of ACH-4471, First Orally-Administered Small Molecule Complement Factor D Inhibitor
Company's Proprietary Complement Platform Focuses on Advancing Factor D Inhibitor Drug Candidates That Could Treat Ultra-Rare Diseases Such as Paroxysmal Nocturnal Hemoglobinuria (PNH) and Other Complement-Mediated Diseases
View HTML
Toggle Summary Achillion Reports 2015 Fourth Quarter and Year-End Financial Results
Strong Balance Sheet to Support Planned 2016 Clinical Expansion of Complement Factor D Platform
View HTML
Toggle Summary Achillion to Present at Two Upcoming Investor Conferences
NEW HAVEN, Conn., March 03, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at two upcoming investor conferences: Cowen and Company 36 th Annual
View HTML
Toggle Summary Achillion to Present at the Deutsche Bank 41st Annual Health Care Conference
NEW HAVEN, Conn., April 28, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the Deutsche Bank 41 st Annual Health Care Conference on
View HTML
Toggle Summary Achillion Reports First Quarter 2016 Financial Results and Provides Update on Clinical Programs
-  Company provides update on HCV collaboration with Janssen; Phase 2b combination study evaluating doublet and triplet regimens for six and eight weeks anticipated to begin in Q3 2016 — -  Strong balance sheet to support planned 2016 clinical expansion of ACH-4471, Achillion's first small molecule
View HTML